France's Novacyt H1 revenue rises on Southern Cross Diagnostics acquisition

By Reuters News


Overview

  • France molecular diagnostics firm's H1 revenue rose 18% yr/yr to £11.6m

  • Gross margin fell to 56% from 66%, mainly due to SCD acquisition and lower Primer Design sales


Outlook

  • Novacyt expects continued organic revenue growth in H2, driven by Instrumentation and Clinical portfolios

  • Company anticipates further opex reductions in H2, with full annualised benefit seen in 2027

  • Novacyt expects Research Use Only segment buying patterns to normalise and uplift sales in H2


Result Drivers

  • SCD ACQUISITION - Revenue growth was partly driven by the acquisition of Southern Cross Diagnostics, which contributed £1.8m in sales but diluted group gross margin due to lower distributor margins and a stock uplift adjustment

  • CLINICAL SEGMENT GROWTH - The Clinical segment delivered over 20% year-on-year revenue growth, driven by demand for reproductive health products and inclusion of SCD sales

  • INSTRUMENTATION DEMAND - Instrumentation segment revenue grew about 30% year-on-year, reflecting continued market adoption of the LightBench Discover platform


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted EBITDA

-GBP 3.58 mln


Reuters Recommended Reads

  • Sept 29 - France's LightOn H1 revenue jumps 51% on higher Paradigm license sales

  • Sept 28 - France's Genfit H1 revenue falls due to absence of milestone payments

  • Sept 29 - France's GenSight Biologics H1 net loss widens on higher R&D expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.